Summer is coming!
Pharmaceutical Technology Europe
As summer approaches, the European pharmaceutical industry is preparing for a well-deserved break. However, some will leave the arena on a higher note than others. While big pharma is embracing the globalization of the industry and suffering under extreme pressure to improve performance, the biopharmaceutical sector retires with a smile and reasons to celebrate.
As summer approaches, the European pharmaceutical industry is preparing for a well-deserved break. However, some will leave the arena on a higher note than others. While big pharma is embracing the globalization of the industry and suffering under extreme pressure to improve performance, the biopharmaceutical sector retires with a smile and reasons to celebrate.
Dr Bibiana Campos-Seijo
On a national level, the UK's contribution to biotechnology and, in particular, stem cell research has been outstanding. Interestingly, this has nothing to do with new technologies or discoveries, but with groundbreaking changes in regulation. In what became an overwhelming victory (336 versus 176 votes) on 19 May, the House of Commons voted in favour of the use of interspecies hybrid embryos for stem cell research.
Although this is a controversial move, the government hopes it will provide researchers and scientists with the legal framework they require to achieve a better understanding of disease processes, and pursue new cures and treatments. When asked, the UK's Prime Minister, Gordon Brown, said: "the question is not whether they [hybrid embryos] should exist, but how their use should be controlled."
On a European level there has been a landmark development: the European Parliament launch of the European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). This initiative aims to create a European bank or collection of samples of biological human material including blood, tissue, DNA, proteins and other genetic material. This project will also protect the data from inappropriate use by harmonizing national legislations and guarantee the quality of the samples by establishing common standards for collection and storage.
At Pharmaceutical Technology Europe, we are looking forward to the summer too! By the time this issue goes out we'll be working hard on the publication of our Buyers' Guide, an essential directory that places your products and services in front of the industry's key buyers, and on the development of a new management section that will see the light in our September issue.
Have a fantastic summer!
Dr Bibiana Campos-Seijo
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
